Table 3 Adjusted prevalence ratio of symptoms lasting over 12 weeks

From: A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents

Report of symptoms lasting over 12 weeks

Overalla

p-value

Within seropositivesa

p-value

Within seronegativesa

p-value

n = 1034b PR (95%CI)

n = 570b PR (95%CI)

n = 464b PR (95%CI)

Sex

Female

1.0 (ref)

–

1.0 (ref)

–

1.0 (ref)

 
 

Male

1.1 (0.8;1.6)

0.665

1.1 (0.7;1.8)

0.723

0.9 (0.4–1.9)

0.875

Age (years)

 

1.1 (1.0;1.2)*

0.012

1.1 (1.0;1.3)*

0.021

1.1 (0.9–1.2)

0.261

Serological status

Seronegative

1.0 (ref)

–

–

–

 

–

 

Seropositive

1.8 (1.2;2.8)**

<0.01

–

–

 

–

Chronic condition

No

1.0 (ref)

–

1.0 (ref)

–

1.0 (ref)

–

 

Yes

3.6 (2.3;5.5)**c,d

<0.01

3.5 (2.0;6.1)**c,d

<0.01

2.9 (1.3–6.5)**c,d

<0.01

Parental education

Tertiary

1.0 (ref)

–

1.0 (ref)

–

1.0 (ref)

–

 

Secondary

1.2 (0.7;2.0)c,d

0.471

1.3 (0.6;2.5)c,d

0.469

1.2 (0.7;2.0)c,d

0.469

 

Primary

1.9 (0.8;4.7)c,d

0.365

1.7 (0.5;5.2)c,d

0.369

1.9 (0.8;4.6)c,d

0.369

Financial situation

High

1.0 (ref)

–

1.0 (ref)

–

1.0 (ref)

–

 

Average to poor

2.5 (1.4;4.6)*c,d

<0.05

3.0 (1.5;6.2)*c,d

<0.05

1.2 (0.9–3.4)c,d

0.501

  1. aPrevalence ratio and 95% confidence interval are from Poisson regression with random effect on the household using the GLMMadaptive package in R and are adjusted for age, sex, or both according to independent variable, using a two-sided Likelihood Ratio Test, without adjustments for multiple comparisons.
  2. bComplete case analysis. For each model presented, missing data in the covariates were excluded.
  3. cAdjusting for age and sex.
  4. dUnadjusted estimates are presented in Table S6.
  5. *indicates p-value < 0.05.
  6. **indicates p-value < 0.01.
Back to article page